How we treat Merkel cell carcinoma: within and beyond current guidelines

被引:26
作者
Park, Song Y. [1 ]
Doolittle-Amieva, Coley [1 ]
Moshiri, Yasman [1 ]
Akaike, Tomoko [1 ]
Parvathaneni, Upendra [2 ]
Bhatia, Shailender [3 ]
Zaba, Lisa C. [4 ]
Nghiem, Paul [1 ,2 ]
机构
[1] Univ Washington South Lake Union, Div Dermatol, Seattle, WA 98109 USA
[2] Univ Washington, Dept Radiat Oncol, Seattle, WA 98109 USA
[3] Univ Washington, Dept Med, Seattle, WA 98109 USA
[4] Stanford Univ, Dept Dermatol, Palo Alto, CA 94304 USA
关键词
customized treatment; imaging; immunotherapy; Merkel cell carcinoma; multidisciplinary management; radiotherapy; surgery; surveillance; FRACTION RADIATION-THERAPY; CHEMOTHERAPY; RECURRENCE; CANCER; RADIOTHERAPY; MULTICENTER; ANTIBODIES; MANAGEMENT; PROGNOSIS; DIAGNOSIS;
D O I
10.2217/fon-2020-1036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with a high risk of local recurrence and distant metastasis. Optimal care of this potentially life-threatening cancer is critical but challenging because: physicians are often unfamiliar with its management due to rarity, and MCC management remains controversial, in part because it is rapidly evolving across multiple specialties. While guidelines offer a broad overview of management, they are often not sufficient when making decisions for individual patients. Herein, we present a literature review as well as practical approaches adopted at our institutions for staging, surveillance and therapy of MCC. Each of these areas are discussed in light of how they can be appropriately customized for prevalent but challenging situations. We also provide representative examples of MCC patient scenarios and how they were managed by a multidisciplinary team to identify suitable evidence-based, individualized treatment plans. Lay abstract Merkel cell carcinoma (MCC) is a skin cancer with a high risk of recurrence and distant spread. Optimal care of this cancer is important. However, management is challenging because it is rare and its treatment is continuously evolving across multiple specialties. While treatment guidelines offer a broad overview of management, they are often not detailed enough to provide appropriate patient-specific assistance. Herein, we present a review of recent studies and our suggestions relevant to MCC staging, surveillance and treatment options. Each of these areas are discussed in light of how they can be appropriately customized for challenging situations often encountered by practitioners. We also provide representative examples of MCC patient scenarios and how they were managed by a multidisciplinary team to identify evidence-based, individualized treatment plans.
引用
收藏
页码:1363 / 1377
页数:15
相关论文
共 72 条
[1]  
AHMADZADEHFAR H, 2014, J NUCL MED S1, V55, P55
[2]   High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma [J].
Akaike, T. ;
Qazi, J. ;
Anderson, A. ;
Behnia, F. S. ;
Shinohara, M. M. ;
Akaike, G. ;
Hippe, D. S. ;
Thomas, H. ;
Takagishi, S. R. ;
Lachance, K. ;
Park, S. Y. ;
Tarabadkar, E. S. ;
Iyer, J. G. ;
Blom, A. ;
Parvathaneni, U. ;
Vesselle, H. ;
Nghiem, P. ;
Bhatia, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (02) :319-327
[3]   Merkel cell carcinoma: Prognosis and treatment of patients from a single institution [J].
Allen, PJ ;
Bowne, WB ;
Jaques, DP ;
Brennan, MF ;
Busam, K ;
Coit, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2300-2309
[4]   Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted Lu-177-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases? [J].
Basu, Sandip ;
Ranade, Rohit .
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2016, 44 (02) :85-87
[5]   Merkel cell carcinoma [J].
Becker, J. C. .
ANNALS OF ONCOLOGY, 2010, 21 :81-85
[6]   Merkel cell carcinoma [J].
Becker, Juergen C. ;
Stang, Andreas ;
DeCaprio, James A. ;
Cerroni, Lorenzo ;
Lebbe, Celeste ;
Veness, Michael ;
Nghiem, Paul .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3
[7]   Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma [J].
Bhatia, Shailender ;
Longino, Natalie V. ;
Miller, Natalie J. ;
Kulikauskas, Rima ;
Iyer, Jayasri G. ;
Ibrani, Dafina ;
Blom, Astrid ;
Byrd, David R. ;
Parvathaneni, Upendra ;
Twitty, Christopher G. ;
Campbell, Jean S. ;
Le, Mai H. ;
Gargosky, Sharron ;
Pierce, Robert H. ;
Heller, Richard ;
Daud, Adil I. ;
Nghiem, Paul .
CLINICAL CANCER RESEARCH, 2020, 26 (03) :598-607
[8]   Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma [J].
Bhatia, Shailender ;
Miller, Natalie J. ;
Lu, Hailing ;
Longino, Natalie V. ;
Ibrani, Dafina ;
Shinohara, Michi M. ;
Byrd, David R. ;
Parvathaneni, Upendra ;
Kulikauskas, Rima ;
ter Meulen, Jan ;
Hsu, Frank J. ;
Koelle, David M. ;
Nghiem, Paul .
CLINICAL CANCER RESEARCH, 2019, 25 (04) :1185-1195
[9]   Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management [J].
Bichakjian, Christopher K. ;
Lowe, Lori ;
Lao, Christopher D. ;
Sandler, Howard M. ;
Bradford, Carol R. ;
Johnson, Timothy M. ;
Wong, Sandra L. .
CANCER, 2007, 110 (01) :1-12
[10]  
Blackmon Jonathan T, 2017, JAAD Case Rep, V3, P185, DOI 10.1016/j.jdcr.2017.02.003